Regenxbio Inc is primarily active in the biotechnology industry.

The main competitors of Regenxbio Inc in the market include other gene therapy companies such as bluebird bio, Sangamo Therapeutics, uniQure, and Spark Therapeutics.

Regenxbio Inc. is a biotechnology company focused on the development and commercialization of gene therapy treatments. Founded in 2008, Regenxbio has grown into a leading player in the field of gene therapy, with a strong emphasis on adeno-associated virus (AAV) vector technology. The company has developed a proprietary NAV Technology Platform, which enables the precise and targeted delivery of therapeutic genes to specific cells in the body. Regenxbio has made significant strides in advancing gene therapy treatments for various genetic disorders, including ophthalmic, metabolic, and neurodegenerative diseases. As an innovative and pioneering company, Regenxbio is committed to revolutionizing the future of gene therapies.

Regenxbio Inc has achieved several significant milestones in its history. One notable milestone is the successful completion of a Phase I clinical trial for its lead product candidate, RGX-314. This novel gene therapy aims to treat wet age-related macular degeneration (AMD). Additionally, Regenxbio has entered into partnerships with renowned pharmaceutical companies, including Novartis and Audentes Therapeutics, to further expand its gene therapy platform. The company has also garnered regulatory approvals for its gene therapy products, including FDA breakthrough therapy designation for RGX-314. These achievements highlight Regenxbio's commitment to developing innovative gene therapies for various genetic disorders, including eye diseases.

Regenxbio Inc is primarily present in the United States.

Regenxbio Inc is a renowned biotechnology company specializing in the development of life-changing gene therapies for patients suffering from severe diseases. The company's core values revolve around innovation, scientific excellence, and patient-centric focus. Regenxbio Inc is dedicated to improving the lives of individuals by harnessing the power of gene therapy to address unmet medical needs. With a commitment to integrity, collaboration, and transparency, Regenxbio Inc strives to bring groundbreaking treatments to patients, build strong partnerships, and continuously push the boundaries of scientific discovery. Their corporate philosophy embodies a relentless pursuit of transformative therapies to revolutionize healthcare and provide hope for those in need.

Analysts currently set an average price target of 30,76 USD for the Regenxbio stock (median: 29,58 USD), implying +290,3 % versus the latest price. The consensus is based on 19 analyst ratings.

Regenxbio Analyytikkojen kursstavoitteet 2026

19 analysts currently rate the Regenxbio stock: 17 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Regenxbio to generate revenue of 172,01 M USD and earnings per share of −3,42 USD.

Regenxbio Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Regenxbio share trades at 9,19 EUR (10,72 USD).

The Regenxbio share (RGNX) is listed on 4 stock exchanges, including: NASDAQ (RGNX), Frankfurt (RB0.F), München (RB0.MU), Düsseldorf (RB0.DU).

Regenxbio Inc is a biopharmaceutical company focused on the development of gene therapies for rare genetic diseases. The company's business model is based on the discovery, development, and commercialization of innovative gene therapies to improve the lives of patients worldwide. Regenxbio was founded in 2009 and is headquartered in Rockville, Maryland (USA). As a pioneer in the field of gene therapy, the company has developed an extensive platform based on AAV vector technology. This platform allows Regenxbio to develop customized gene therapies and create new treatment options for patients with rare diseases. Regenxbio's research and development focuses on the identification and characterization of AAV vectors, each capable of transporting and expressing specific genes. Regenxbio has developed a wide range of AAV vectors tailored to the needs of patients with different conditions. The company has partnerships with numerous pharmaceutical and biotech companies such as Novartis, Alexion Pharmaceuticals, and Pfizer. These partnerships focus on the development of gene therapy solutions for various diseases such as cystic fibrosis, hemophilia, and Fabry disease. Regenxbio also has its own pipeline of gene therapy products in various stages of clinical development. Some of the products developed by Regenxbio include: - RGX-314: A gene therapy for the treatment of wet age-related macular degeneration (AMD). This therapy is based on the use of AAV8 vectors to transport the gene for the anti-VEGF antibody into the eye. - RGX-121: A gene therapy for the treatment of mucopolysaccharidosis type II (MPS II). This therapy is based on the use of AAV9 vectors to transport the gene for the enzyme iduronate-2-sulfatase (IDS) into the brain. - RGX-111: A gene therapy for the treatment of mucopolysaccharidosis type I (MPS I). This therapy is based on the use of AAV9 vectors to transport the gene for the enzyme alpha-L-iduronidase (IDUA) into the brain. - RGX-501: A gene therapy for the treatment of hemophilia A. This therapy is based on the use of AAV8 vectors to transport the gene for factor VIII into the liver. Regenxbio is on its way to becoming one of the leading companies in the gene therapy industry. The customized platform for gene therapy development, close collaboration with partners, and the company's own pipeline of gene therapy products should bring growth and success to the company in the future.

odotettu liikevaihto Regenxbio on 172,01 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Regenxbio on −176,89 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Regenxbio:n hinta-voitto-suhde (P/E) on tällä hetkellä −3,14. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Regenxbio-osakkeen arvostusta.

Regenxbio:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,23. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Regenxbio-osakkeen arvostuskennuslukuna.

Regenxbio:n Eulpool-laatuscore on 3/10.

Regenxbio:n ISIN on US75901B1070. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Regenxbio:n WKN on A140E0. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Regenxbio:n ticker on RGNX. Tämä pörssinoteeraus käytetään Regenxbio-osakkeiden kauppaan pörssissä.

Regenxbio maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Regenxbio kuuluu sektoriin 'Terveydenhuolto'.

Regenxbio:n osingot jaetaan valuutassa USD.